These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

608 related items for PubMed ID: 22480822

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22. Agonist trigger: what is the best approach? Agonist trigger with aggressive luteal support.
    Engmann L, Benadiva C.
    Fertil Steril; 2012 Mar; 97(3):531-3. PubMed ID: 22245529
    [Abstract] [Full Text] [Related]

  • 23. Reducing the dose of human chorionic gonadotropin in high responders does not affect the outcomes of in vitro fertilization.
    Schmidt DW, Maier DB, Nulsen JC, Benadiva CA.
    Fertil Steril; 2004 Oct; 82(4):841-6. PubMed ID: 15482757
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Cycles triggered with GnRH agonist: exploring low-dose HCG for luteal support.
    Castillo JC, Dolz M, Bienvenido E, Abad L, Casañ EM, Bonilla-Musoles F.
    Reprod Biomed Online; 2010 Feb; 20(2):175-81. PubMed ID: 20113955
    [Abstract] [Full Text] [Related]

  • 27. Comparison of "triggers" using leuprolide acetate alone or in combination with low-dose human chorionic gonadotropin.
    Shapiro BS, Daneshmand ST, Garner FC, Aguirre M, Hudson C.
    Fertil Steril; 2011 Jun 30; 95(8):2715-7. PubMed ID: 21550042
    [Abstract] [Full Text] [Related]

  • 28. A gonadotropin releasing hormone agonist trigger of ovulation with aggressive luteal phase support for patients at risk of ovarian hyperstimulation syndrome undergoing controlled ovarian hyperstimulation.
    Liang IT, Huang HY, Wu HM, Wang HS, Yu HT, Huang SY, Chang CL, Soong YK.
    Taiwan J Obstet Gynecol; 2015 Oct 30; 54(5):583-7. PubMed ID: 26522115
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Is the GnRH Antagonist Protocol Effective at Preventing OHSS for Potentially High Responders Undergoing IVF/ICSI?
    Xing W, Lin H, Li Y, Yang D, Wang W, Zhang Q.
    PLoS One; 2015 Oct 30; 10(10):e0140286. PubMed ID: 26468951
    [Abstract] [Full Text] [Related]

  • 32. Reproductive Outcome After GnRH Agonist Triggering With Co-Administration of 1500 IU hCG on the Day of Oocyte Retrieval in High Responders: A Long-Term Retrospective Cohort Study.
    Abdulkhalikova D, Bokal EV, Stimpfel M, Ciglar P, Korosec S.
    Front Endocrinol (Lausanne); 2022 Oct 30; 13():826411. PubMed ID: 35464066
    [Abstract] [Full Text] [Related]

  • 33. Towards an optimal luteal support modality in agonist triggered cycles: a randomized clinical trial.
    Elgindy EA, Sibai H, Mostafa MI, Gibreel A, Darwish E, Maghraby H.
    Hum Reprod; 2018 Jun 01; 33(6):1079-1086. PubMed ID: 29562260
    [Abstract] [Full Text] [Related]

  • 34. Independent serum markers of corpora lutea function after gonadotropin-releasing hormone agonist trigger and adjuvant low dose human chorionic gonadotropin in in vitro fertilization.
    Kaye L, Griffin D, Thorne J, Neuber E, Nulsen J, Benadiva C, Engmann L.
    Fertil Steril; 2019 Sep 01; 112(3):534-544. PubMed ID: 31227286
    [Abstract] [Full Text] [Related]

  • 35. Daily low-dose hCG stimulation during the luteal phase combined with GnRHa triggered IVF cycles without exogenous progesterone: a proof of concept trial.
    Andersen CY, Elbaek HO, Alsbjerg B, Laursen RJ, Povlsen BB, Thomsen L, Humaidan P.
    Hum Reprod; 2015 Oct 01; 30(10):2387-95. PubMed ID: 26209535
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Circulating luteinizing hormone level after triggering oocyte maturation with GnRH agonist may predict oocyte yield in flexible GnRH antagonist protocol.
    Chen SL, Ye DS, Chen X, Yang XH, Zheng HY, Tang Y, He YX, Guo W.
    Hum Reprod; 2012 May 01; 27(5):1351-6. PubMed ID: 22419746
    [Abstract] [Full Text] [Related]

  • 38. Gonadotropin-releasing hormone agonist trigger: the way to eliminate ovarian hyperstimulation syndrome--a 20-year experience.
    Kol S, Itskovitz-Eldor J.
    Semin Reprod Med; 2010 Nov 01; 28(6):500-5. PubMed ID: 21082509
    [Abstract] [Full Text] [Related]

  • 39. Assessing the adequacy of gonadotropin-releasing hormone agonist leuprolide to trigger oocyte maturation and management of inadequate response.
    Chang FE, Beall SA, Cox JM, Richter KS, DeCherney AH, Levy MJ.
    Fertil Steril; 2016 Oct 01; 106(5):1093-1100.e3. PubMed ID: 27341988
    [Abstract] [Full Text] [Related]

  • 40. The gonadotropin-releasing hormone antagonist protocol--the protocol of choice for the polycystic ovary syndrome patient undergoing controlled ovarian stimulation.
    Kol S, Homburg R, Alsbjerg B, Humaidan P.
    Acta Obstet Gynecol Scand; 2012 Jun 01; 91(6):643-7. PubMed ID: 22428986
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 31.